BSX — Boston Scientific Corporation

The market is bearish because the August 25, 2026 cybersecurity incident forced BSX to withdraw Q3 and FY2026 sales/EPS guidance on September 8–9, 2026, compounding already decelerating growth: Q2 2026 organic growth guidance was cut to 5–6%, U.S. electrophysiology growth slowed to ~3%, and WATCHMAN decelerated to low single digits amid Abbott/J&J competition. The stock's 1-week -10.08% and 6-month -37.83% returns reflect a swift repricing to a 'lost year' narrative, even as analyst consensus remains a Moderate Buy with targets being cut.

Revenue growth has decelerated sharply: after ~20–23% YoY gains through 2024 and mid-2025, growth slowed to +11.6% in Q1 2026 and +7.5% in Q2 2026. Operating margin improved from mid-teens in 2024 to ~21.6% in Q2 2026 (gross margin ~70.7%), but net income is volatile ($0.90 EPS in Q1 2026 vs. $0.61 in Q2 2026) and the recent cyber incident will disrupt Q3/FY 2026. FCF remains strong—$1.279B in Q2 2026, TTM ~$3.6B—but the growth slowdown in EP and WATCHMAN looks structural until pipeline and competitive dynamics improve.

As of 2026-09-13, BSX trades at 17.33x TTM EPS ($2.482) and ~13.1x next-FY consensus EPS ($3.289), versus a 5-year average P/E of 67.5 (distorted by depressed prior earnings) and P/S of 3.04 vs. a 5-year average of 6.22. The stock is cheap versus its own history on P/S and forward earnings, and PEG of 0.378 screens low, but the discount reflects real execution risk, guidance withdrawal, and competitive share loss rather than a clear mispricing.

The market is pricing 2026 as a lost year: at $42.98, the stock sits at ~13x next-FY EPS of $3.289, a multiple that assumes either a solid 2027 recovery or further estimate cuts. If the cyber incident is contained and Q3/Q4 show backlog recovery, the multiple could expand toward the high-teens, implying $55–60; if guidance is cut again, the 'cheap' forward P/E may be an illusion built on stale estimates. Watch the Q3 call for quantified cyber impact and initial 2027 commentary—that will reset the earnings base.

As of 2026-09-13, RSI was 33.28—near oversold but not below 30—while price was 10.6% below its 20-day SMA, 8.43% below its 50-day SMA, and 34.58% below its 200-day SMA. The 1-week -10.08% and 6-month -37.83% returns confirm a strong downtrend. An oversold bounce is possible, but without a reclaim of the 50-day SMA or RSI moving above 50, the trend remains negative; entry-timing favors waiting for stabilization rather than catching the falling knife.

• Sector-wide medtech cybersecurity risk: the August 2026 attack on BSX follows similar incidents at Abbott, Stryker, Medtronic, and Novo Nordisk, raising IT and regulatory scrutiny across medical devices.
• Competitive intensification in high-growth segments: Abbott and Johnson & Johnson are pressuring BSX in electrophysiology and structural heart (WATCHMAN), forcing reliance on pipeline execution.
• Stabilizing interest rates: lower discount rates could support medtech multiples, but BSX's de-rating is company-specific execution risk, not macro-driven.
• Hospital capital spending and procedure volumes: device demand is tied to hospital budgets and surgical volumes, which remain generally healthy but could be disrupted by cyber-related order backlogs.
• Regulatory and legal scrutiny from cyberattack: potential HIPAA/data-privacy investigations, remediation costs, and insurance recovery uncertainty.

• Q3 2026 earnings call: management will quantify the cyberattack's revenue/EPS damage and provide a recovery timeline, a critical reset for estimates.
• Initial 2027 outlook: consensus expects a muted transition year; any sign of reaccelerating EP/WATCHMAN growth or restructuring savings could lift the stock.
• Restructuring program: $700–$800M in pre-tax charges targeting ~$500M annual pre-tax savings, with execution on margin protection a potential positive.
• Pipeline and competitive response: new product launches or clinical data in EP/structural heart could stabilize share.

• Cyber incident worse than expected: additional manufacturing/shipping disruptions, delayed order processing, or a second guidance cut could further depress Q3/FY 2026 results.
• Structural share loss in EP and WATCHMAN: U.S. EP growth slowed to ~3% and WATCHMAN to low single digits amid Abbott/J&J competition; if this persists, the long-term growth algorithm is impaired.
• Restructuring execution risk: $700–$800M in charges may not yield the planned $500M savings, and charges could mask underlying margin pressure.
• Valuation trap: the stock looks cheap on trailing/forward numbers, but estimates may still be too high if the cyber disruption and competitive pressures persist.

BSX is a high-quality medtech franchise with strong margins (~21.6% operating), robust FCF (~$3.6B TTM), and a solid balance sheet, but 2026 is a lost year: the cyberattack, guidance withdrawal, and EP/WATCHMAN deceleration have created real execution risk. At $42.98 (13x next-FY EPS), the stock is not expensive, but it is not a clear buy until management quantifies the cyber damage and shows core growth stabilizing. Contrarian investors could scale in near $40–45, but the next few months carry high estimate risk.

I apply a 16x forward P/E to next-FY consensus EPS of $3.289, giving $52.62, rounded to $52.00. This multiple sits above the current ~13x forward P/E to reflect the quality margin/FCF profile, but below historical medtech multiples due to execution risk and the cyber incident. A cross-check using 16x EV/EBITDA on ~$5.55B EBITDA also lands near $49–53 per share.